<DOC>
	<DOC>NCT01763554</DOC>
	<brief_summary>Review of the medical files of 69 patients with neuroendocrine tumours who were treated at the CCI from January/10 - July/12 with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP). Efficacy, safety, and other relevant data will be collected.</brief_summary>
	<brief_title>Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and July 31, 2012</brief_title>
	<detailed_description>Neuroendocrine tumours comprise a spectrum of rare neoplasms. Data analysis will be conducted to obtain efficacy, safety, and other relevant data from each Lu-177 DOTA-TATE treatment.</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Radiopharmaceuticals</mesh_term>
	<criteria>Male or female ≥ 14 90 years of age Presence of histologically proven NET tumour(s) Serum creatinine ≤ 150 µmol/L, and a measured GFR using plasma clearance of ≥50 mL/min Haemoglobin concentration 5.5 mmol/L; WBC ≥ 2*109/L; platelets ≥ 100*109/L Liver function tests (serum albumin, total bilirubin, ALT, AST and alkaline phosphatase) ≤ 3X the upper limit of normal Potential for surgery with curative intent Surgery, radiation therapy, cytotoxic chemotherapy, embolization or other investigative therapy (interferons, mTOR inhibitors) within 12 weeks of enrollment Known brain metastases unless these metastases have been treated and stabilized (confirmed by CT) for ≥ 6 months prior to enrollment Uncontrolled congestive heart failure Receiving concomitant medications which decrease renal function Uncontrolled diabetes mellitus Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lu-177</keyword>
	<keyword>Lutetium-177</keyword>
	<keyword>DOTA-TATE</keyword>
	<keyword>Neuroendocrine tumors</keyword>
	<keyword>radiopharmaceutical</keyword>
</DOC>